Exvivo Therapeutics is a clinical-stage biopharmaceutical company developing pneumococcal conjugate vaccines using its proprietary XpressCF cell-free protein synthesis platform, which enables production of complex vaccines with enhanced immunological properties and reduced carrier suppression compared to conventional manufacturing methods. The company's lead candidates include VAX-31 (a broad-spectrum 31-valent vaccine) and VAX-24 (a 24-valent vaccine) designed for both adult and pediatric markets, targeting large commercial opportunities in prevention of pneumococcal disease, which affects hundreds of thousands annually and is increasingly complicated by antibiotic resistance. Exvivo operates a non-integrated business model with manufacturing partnerships through Lonza, Thermo Fisher Scientific, and Sutro Biopharma, and generates revenue through vaccine sales following regulatory approval, with royalty obligations to manufacturing and technology partners.